YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Global trade is moving away from easy cross border flows, with more tariffs and restrictions reshaping how companies grow. Businesses that can still lift earnings quickly, while keeping their finances in decent shape, look more valuable wh…
The Federal Reserve just lifted interest rates again to tackle stubborn inflation, which puts real pressure on weaker balance sheets and slow growing businesses. In this environment, investors may focus on companies that analysts expect to…
Bond markets have been shaken by 10-year Treasury yields hitting a 19-year high, which raises borrowing costs and forces investors to rethink where future returns might come from. That kind of reset often shifts attention toward businesses…
CAMBRIDGE, Mass., September 23, 2026--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat…
Mid-cap U.S. healthcare stocks have exhibited strong momentum traits year to date, with several names earning A-range momentum grades that indicate stronger price performance trends relative to sector peers. Seeking Alpha's Quant Momentum…
Comparing the Vanguard Health Care ETF (NYSEMKT:VHT) and State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) involves choosing between broad healthcare sector coverage and a concentrated focus on pharmaceutical industry players. These…
The Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) provides broad healthcare exposure at a fraction of the cost of the State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH), which targets a specific industry niche. Investors seeking…
Amylyx Pharmaceuticals (NASDAQ: AMLX) has skyrocketed more than 247% since the start of the year, turning what was once a beaten-down biotech stock into one of the hottest GLP-1 plays on the market. The question, of course, is whether it c…
Eli Lilly (NYSE: LLY) was the second company to market a GLP-1 drug. That's important to keep in mind as you look at the competitive landscape for this new class of weight-loss drugs. In some ways, investors do need to worry that companies…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As the month of August 2026 comes to a close, the broader stock market has exhibited a mix of late-summer consolidati…
A study suggests high borrow costs are a good indicator that a stock will lag the broader market. - Getty Images/iStock Certain stocks are such poor bets that they are likely to lose ground even in bull markets. These "loser" stocks are on…
Eurozone private sector credit growth is gaining pace, which points to households and businesses feeling more confident about borrowing for spending and investment. That kind of backdrop can support companies with healthy balance sheets an…
Germany's Ifo index has reached a one year high, which hints at a more confident backdrop for companies planning to grow earnings rather than just defend margins. That creates an interesting setting for investors looking for earnings momen…
The stock of clinical-stage biotech Amylyx Pharmaceuticals (NASDAQ: AMLX) was a hot item among investors over the past five trading days. One of its investigational medicines did very well in a late-stage clinical trial; this, combined wit…
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026. Shares closed Monday down 0.9% at $21.43, then traded 15.7% higher at $24.80 after hours after the com…
Shares of Amylyx Pharmaceuticals AMLX surged 63.8% yesterday after it announced positive top-line data from the phase III LUCIDITY study. This study evaluated its lead candidate, avexitide, a GLP-1 receptor antagonist, in participants with…
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) soared to a new three-year high on Tuesday after its treatment candidate for post-bariatric hypoglycemia (PBH) reported strong results in phase 3 clinical studies, paving the way for its looming co…
NASDAQ sign at times square at night by Lucky-photographer via iStock The S&P 500 Index ($SPX) (SPY) closed down by -0.69% on Tuesday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down by -0.22%, and the Nasdaq 100 Index ($IUXX) (…
Biotechnology and medical scientific research by Brian A Jackson via Shutterstock Amylyx (AMLX) stock ripped higher on Tuesday after the pharmaceutical firm reported promising Phase 3 clinical trial data for its candidate drug, avexitide.…
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.8%.The iShares Biotechnology ETF (IBB) was up 1%.In corporate news, Haemonetic…
Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.7%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, Amylyx…
The S&P 500 Index ($SPX) (SPY) is down by -0.61% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down by -0.10%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -1.76%. E-mini S&P futures (ESU26) are down -0.68%, and September E…
[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures edged lower on Tuesday as investors weighed a fresh surge in crude oil prices driven by stalled diplomatic talks and lingering concerns o…
The S&P 500 Index ($SPX) (SPY) is down by -0.42% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down by -0.21%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -1.17%. E-mini S&P futures (ESU26) are down -0.51%, and September E…
The pharmaceutical sector differs from many industries as stock performance often depends less on near-term results and more on the success of products in development. For biotech companies, clinical and regulatory developments can sharply…
(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming clinical results. Halozyme Therapeutics Inc. (HALO) Halozyme is a biopharmaceutical co…
[Lower Manhattan Cityscape] Art Wager/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. M…
(RTTNews) - As Warren Buffett once said, "If you find three wonderful businesses in your life, you'll get very rich." His message underscores the importance of identifying a handful of exceptional companies capable of delivering sustained…
[Wall Street New York stock exchange stock market] alexsl Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. M…
[Citibank headquarters in Canary Wharf, London, UK] VV Shots Citi released its roadmap for the second half of 2026, including a macro-to-micro view of equity sectors. "Our recently revised S&P 500 (SPY [https://seekingalpha.com/symbol/SPY]…
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best low-priced pharma stocks on this list. TheFly reported on June 25 that Guggenheim raised it…
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best low-priced pharma stocks on this list. TheFly reported on June 18 that Jefferies an…
On May 15, 2026, Almitas Capital disclosed a purchase of 143,527 additional shares of ASA Gold and Precious Metals Limited(NYSE:ASA), an estimated $9.69 million trade based on quarterly average pricing. What happened According to a Securit…
Key Points Almitas Capital bought 143,527 shares of ASA last quarter, with an estimated transaction value of $9.69 million based on average quarterly prices. Meanwhile, the quarter-end ASA position value increased by $9.80 million, reflect…
Key Points Interested in Amylyx Pharmaceuticals, Inc.? Here are five stocks we like better. Amylyx stock is gaining attention as multiple pipeline programs move toward important clinical milestones in 2026. The company’s Avexitide candidat…
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is among the best pharmaceutical stocks. TheFly reported on May 7 that AMLX reported first-quarter 2026 results…